We are pleased to announce that Reborna has been selected as a finalist in all three categories we entered — Biotech Company of the Year, Financing Deal of the Year, and Licensing Deal of the Year — at the Citeline Japan Awards 2025.

Now in its fourth year, the Citeline Japan Awards celebrate outstanding innovation and progress in Japan’s pharmaceutical and biotechnology industries, highlighting the country’s significant contributions to the global healthcare market.

The winners will be announced at the awards ceremony on Tuesday, October 21, 2025.

For more information, please visit the link below:
https://www.citeline.com/ja-jp/awards/citelinejapanawards

[About Reborna Biosciences, Inc.]
Reborna is engaged in drug discovery research for oral drugs that show disease-modifying effects through normalizing RNA function by using small molecule drugs with a high affinity for RNA. By targeting RNA that governs protein synthesis as a drug discovery target, we aim to provide drugs that offer a novel approach to diseases that have previously proven difficult to treat. We will contribute to society by providing new drugs that enable patients suffering from rare genetic diseases and their families to feel that they have been reborn.

For more information, please visit our website: http://rebornabiosciences/en/.com